HMGBiotech has joined the conference “Goodbye Flat Biology: Next Generation Cancer Models” promoted by EACR, through a poster presentation by Dr. Andrea Lamarca.
Speech at Berlin EACR Conference: Mesothelioma and HMGB1 BoxA Read More »
A recent research has highlighted a groundbreaking discovery concerning the connection between HMGB1 released by mesothelial cells and the development of asbestos-induced mesothelioma.
Unveiling the Mechanism Behind Asbestos-Induced Mesothelioma Read More »
Liam Colley, HMGBiotech’s researcher, gave a speech about “The role of CXCR4 in Triggering Immunosurveillance in the Malignant Mesothelioma Tumor Environment”.
HMGBiotech at CICON- International Cancer Immunotherapy Conference 2023 Read More »
HMGB1 has been shown to play a key role in Parkinson’s disease pathogenesis. Research and studies targeting High Mobility Group Box 1 (HMGB1) protein in Parkinson’s disease (PD) has recently emerged, with promising results in the inhibition of HMGB1.
HMGB1, a Potential Game-Changer in Parkinson’s Research Read More »
Recent studies showed HMGB1’s role in the fight against cancer. HMGB1 is increasingly associated with tumor stages, prognosis, immune response and drug resistance.
HMGB1 could be a game-changer in cancer research Read More »
Latest researches showed that HMGB1 is involved in causing ischemic stroke by ehnancing inflammation and tissue damage in cerebrovascular diseases.
Stroke Research Highlight: HMGB1’s Role in Ischemic Stroke Read More »
HMGBiotech specializes in the production of LPS-free proteins. LPS (Bacterial endotoxin lipopolysaccharide) is a powerful inducer of the immune system and can introduce undesirable variables and limitations in certain experimental setups.
All HMGBiotech recombinant proteins are LPS free Read More »
A recent paper published on Molecular Medicine journal highlights how High Mobility Group Box 1 (HMGB1) and other biomolecules influence fatigue in patients with Crohn’s diseases.
How HMGB1 influences fatigue in patients with Crohn’s diseas Read More »
HMGBiotech Srl has taken part to a study, published in June, in which are discovered CXCL12 as the first fuzzy chemokines heterocomplex reported so far and the unexpected role of the acidic intrinsically disordered region (IDR), in HMGB1●CXCL12 heterocomplex formation.
Anti-inflammatory pharmacological research: unexplored opportunities unveiled Read More »
We and selected third parties use cookies or similar technologies for technical purposes and, with your consent, for experience, measurement and marketing (personalised ads) as specified in the cookie policy. You can freely give, deny, or withdraw your consent at any time by accessing the preferences panel. Denying consent may make related features unavailable. Use the “Accept” button to consent. Use the “Reject” button or close this notice to continue without accepting.